[Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Area of Science:

• Oncology
• Cardiology
• Cancer Therapeutics

Background:

• Cancer treatments can lead to significant cardiotoxic side effects, impacting patient quality of life and survival.
• These effects range from hypertension and heart failure to arrhythmias and thromboembolic events.
• Patients with pre-existing cardiovascular conditions are at higher risk.

Purpose of the Study:

• To highlight the cardiotoxic potential of various cancer treatments.
• To emphasize the role of oncological cardiology in managing these adverse events.
• To underscore the importance of prevention, early diagnosis, and treatment of treatment-related cardiac dysfunction.

Main Methods:

• Review of current oncological treatments and their known cardiovascular side effects.
• Identification of patient populations at increased risk.
• Discussion of the multidisciplinary approach in oncological cardiology.

Main Results:

• Cardiotoxicity is a growing concern with conventional chemotherapy, radiation, targeted therapy, and immune checkpoint inhibitors (ICI).
• Specific cardiotoxic effects include hypertension, thromboembolism, coronary syndromes, heart failure, and arrhythmias.
• Effective management strategies are crucial for mitigating these risks.

Conclusions:

• Oncological cardiology plays a vital role in managing cardiotoxicity in cancer patients.
• Proactive monitoring and intervention are essential for optimizing outcomes.
• Further research is needed to refine prevention and treatment strategies for cancer therapy-induced cardiotoxicity.